Novo Nordisk lays off 400 staff in research & development unit
Reuters
Published Sep 18, 2018 06:55AM ET
Novo Nordisk lays off 400 staff in research & development unit
By Jacob Gronholt-Pedersen
COPENHAGEN (Reuters) - Novo Nordisk (CO:NOVOb), the world's top maker of diabetes drugs, said on Tuesday it will lay off 400 staff in Denmark and China in order to divert funding toward investment in biological and technological innovation.
The firm, which employs more than 42,000 people in 79 countries, has seen growth slow due to pricing pressures in the United States, from where it sources about half its revenue.
"This is not a cost-cutting exercise," Novo's chief science officer Mads Krogsgaard Thomsen said in an interview, noting that his research and development budget will be larger in 2019 than this year.
"Our analysis shows that we have a surplus of manual labor and are lacking competences in the digital sphere, informatics, data science, artificial intelligence and automations."
The company plans to increase investment in innovation within both its core therapy areas and new ones.
As part of this it will establish four new "biotech-like units" this year in Denmark, the United States and the United Kingdom to pursue innovation in areas like stem-cell research.
Novo Nordisk will also increase its investment in automation and digital capabilities, including machine learning and artificial intelligence, it said.
It announced 1,000 job cuts in 2016 as competition among insulin producers increased and prices were squeezed by pharmacy benefit managers (PBMs) who administer drug programs for employers and health plans.
Novo Nordisk said in May that new U.S. legislation aimed at reining in high drug prices would cut its 2019 sales by 1-2 percent.
Shares in Novo Nordisk were trading 0.7 percent higher at 1012 GMT.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.